Turning Point Brands Q3 2026 slides: Modern Oral surges, margins dip

Turning Point Brands (TPB) reported Q3 2026 revenue of $151.1M (+27% YoY) but adjusted EBITDA fell 41% to $18.4M due to investments in its Modern Oral nicotine pouch business. Modern Oral revenue surged 102.9% YoY to $74.4M, now 49% of total sales. Shares fell 7.32% post-earnings, trading at $64.01. The company reaffirmed FY 2026 guidance, projecting Modern Oral net sales of $260-270M and adjusted EBITDA of $70-80M.

Original reporting
Published Nov 9, 2026, 2:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 3:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TPB
Bearish
high confidence
Mentioned
$TPB
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TPBBearishMed
01

Why it matters

Earnings miss on profitability may trigger further sell‑offs, but the strong top‑line growth and strategic investments could support a rebound.

02

Market read

The earnings release provides fresh guidance and performance metrics that directly affect TPB's stock price and the broader nicotine product sector.

03

What to watch

Potential future margin expansion as Modern Oral scales to target 70% margins and upcoming U.S. manufacturing.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Turning Point Brands is transitioning from traditional tobacco to modern oral nicotine products, investing heavily in sales and manufacturing.

Company-level read

Ticker impact

$TPBBearishHigh confidence
Context

Q3 2026 earnings release showing 27% revenue growth but 41% EBITDA decline and guidance range, causing a 7.3% share drop.

Expected impact

likely further pressure as investors digest profitability decline

Evidence & confidence

Earnings miss on EBITDA and wide guidance range typically trigger sell pressure, especially after a 7% drop.

Market effects

Highlights growth in the nicotine pouch segment, may boost peer valuations in tobacco/alternative nicotine space.

U.S. consumer discretionary and tobacco stocks could see short-term volatility.

Limited to U.S. market; no immediate global macro effect.

Counterpoint

Investors could view the revenue beat and aggressive growth as a buying opportunity despite short-term margin pain.

Key entities

  • Turning Point Brands

    NYSE‑listed tobacco and nicotine products company.

  • David Glazek

    CEO providing commentary on organic growth strategy.

Related articles

$TPBMedAI 8/10

Why Turning Point Brands Stock Got Socked Today

Turning Point Brands (NYSE:TPB) stock fell 11% after filing a mixed shelf registration with the SEC, indicating plans to raise capital. The company registered various securities, including common and preferred stock, for potential sale. Proceeds will be used for general corporate purposes. Shelf registrations often concern investors due to potential dilution or increased debt.

$TPBMed

Turning Point Brands Inc (TPB) (Q3 2026) Earnings Call Highlights: Modern Oral Sales Double

Turning Point Brands Inc (TPB) reported Q3 2026 earnings, with adjusted EBITDA declining 41% YoY to $18M due to increased investments. Zig-Zag segment sales fell 15% YoY to $37M, while Stoker's gross margin decreased 416 bps. Modern Oral net revenue guidance for Q4 suggests potential sequential decline or slight increase. CEO David Glazek highlighted strong consumer adoption and positive retail distribution pipeline.

$TPBMed

What Turning Point Brands (TPB) Said on Its Q3 Earnings Call

Turning Point Brands (TPB) reported Q3 gross profit up 21% to $85M, with gross margin at 56%. Stoker's segment sales rose 52%, while Zig-Zag fell 15%. The company reaffirmed its full-year outlook and expects U.S. manufacturing to begin in 2027. TPB ended the quarter with $251M in cash and repurchased $10M of stock.

$TPBMed

Turning Point (TPB) Q3 2026 Earnings Call Transcript

Turning Point (TPB) reported Q3 2026 earnings, highlighting progress in consumer traction, distribution expansion, and infrastructure building. Net sales rose 27% YoY to $151M, driven by Modern Oral. Gross profit increased 21% to $85M, while adjusted EBITDA fell 41% YoY to $18M due to higher sales and marketing investments. Stoker's segment saw 52% YoY sales growth, with Modern Oral nicotine pouch sales up 103% YoY to $74M.

$TPBMed

Turning Point Brands Announces Third Quarter 2026 Results

Turning Point Brands, Inc. (TPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turning Point Brands Announces Third Quarter 2026 Results ● Q3 2026 Modern Oral Gross Sales increased 114.2% to $93.9 million and Net Sales increased 102.9% to $74.4 million, accounting for 49.2% of total company Net Sales ● Reaffirming FY 2026 Modern Oral Gross and